Login to Your Account



Palatin Partners With King On Sexual Dysfunction Candidate

By Kim Coghill


Monday, August 16, 2004
Palatin Technologies Inc. could make more than $250 million via a strategic alliance with King Pharmaceuticals Inc. for the development and commercialization of Palatin's male and female sexual dysfunction candidate, PT-141. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription